Rallybio CORP (RLYB) 13F Positioning & Ownership Changes (Q2 2026)

RLYB ranks #6879 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

RLYB is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

38 institutions disclose a position in RLYB, but none treat it as a major bet — even Pivotal bioVenture Partners Investment Advisor LLC, its most concentrated holder, allocates just 1.6% of its own portfolio to it.

RLYB is down 0.7% today, but institutions show net buying of $57.1M this quarter — a divergence between today's price move and the underlying institutional flow.

RLYB posted net income of $45.6M over the trailing twelve months, and currently trades at a P/E of 2.1.

• Profitable — net income of $45.6M over the trailing twelve months
• Revenue declined 15.1% year over year
• Net income improved year over year, from -$41.7M to $45.6M
• Operating cash flow was negative, using $29.8M in cash
• Current ratio of 14.50x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.07x equity — within a conventional range